Eli Lilly Chief Scientific Officer Dan Skovronsky spoke to CNBC about obesity pills and more on the future of weight loss.
In the final days of 2024, three pharmaceutical giants sued the federal government. In their joint lawsuit, Amgen, Eli Lilly ...
Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...
We recently published a list of the 10 Best Drug Stocks to Buy Now. In this article, we are going to take a look at where Eli ...
Eli Lilly’s profit doubled in the ... expectations on Wall Street but reflect a forecast Lilly made last month. Revenue from the breast cancer treatment Verzenio also helped in the fourth ...
Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.
U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...
For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...
We recently published a list of the 12 Best Long-Term Growth Stocks to Buy Now. In this article, we are going to take a look ...
So far in 2025, the year’s biggest cultural events have served as launchpads for several of the industry's latest cancer ...